Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RMD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsResMed rotates auditor to PwC, appoints Carol Burt lead director as Ron Taylor retires
Filed August 17, 2026 · Period ending August 13, 2026 · ~1 min read
Key Changes
-
medium
Carol Burt appointed lead director effective Nov 15, 2026, succeeding Ron Taylor who retires after 21+ years on the board. Burt has served since 2013 and chairs the Nominating and Governance Committee.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
ResMed dismissed KPMG and appointed PwC as independent auditor for FY2027 after a competitive review. KPMG's FY2025-2026 reports were unqualified with no disagreements or reportable events.
Item 4.01 — Changes in Registrant's Certifying Accountant verify on EDGAR → -
low
Ron Taylor will not stand for reelection at the Nov 18, 2026 annual meeting. His retirement is not due to any disagreement with the company on operations, policies, or practices.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
ResMed disclosed two routine governance transitions. The company rotated its independent auditor from KPMG to PwC for fiscal year 2027 following a competitive review process. KPMG's audit reports for the prior two fiscal years were unqualified, and the company explicitly confirmed no disagreements on accounting principles or reportable events—standard representations for a planned auditor rotation.
On the board side, Ron Taylor is retiring after more than 21 years of service, including 13 years as lead director. Carol Burt, a board member since 2013 who currently chairs the Nominating and Governance Committee, will succeed him as lead director effective November 15, 2026. The filing confirms Taylor's retirement is not due to any disagreement with the company. Both changes reflect normal governance housekeeping—planned auditor rotation and orderly board succession—with no material impact on operations or strategy.
Section-by-Section Diff
Event · Item 4.01 — Changes in Registrant's Certifying Accountant
Item 4.01 — Changes in Registrant's Certifying Accountant filed; see Key Changes for terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
On August 13, 2026, KPMG was dismissed, effective as of that date. ... The reports of KPMG on the Company’s consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended June 30, 2026 and 2025, and the subsequent interim period through August 13, 2026, there were no: (i) disagreements (as defined in Item 304(a) (1) (iv) of Regulation S-K and the related instructions) with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference to such subject matter of the disagreements in their reports; or (ii) reportable events (as defined in Item 304(a) (1) (v) of Regulation S-K).
ResMed dismissed KPMG as its independent auditor effective August 13, 2026, following a competitive review process. KPMG's audit reports for fiscal years 2026 and 2025 were unqualified, and the company explicitly disclosed no disagreements on accounting principles or practices and no reportable events during the relevant periods. This represents a routine auditor rotation with clean representations under Item 304.
Added in current filing · verify on EDGAR →
On August 13, 2026, after completion of the comprehensive review process, the Audit Committee approved the dismissal of KPMG and appointed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm, subject to completion of PwC’s standard client acceptance procedures, for the fiscal year ending June 30, 2027.
The Audit Committee appointed PwC as the company's new independent auditor for fiscal year 2027, subject to PwC completing its standard client acceptance procedures. The appointment followed a comprehensive competitive review process and is part of the planned auditor transition.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In connection with Mr. Taylor’s retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.
Carol Burt has been appointed as lead director, effective November 15, 2026, three days before the annual meeting. This appointment fills the governance role being vacated by Mr. Taylor's retirement.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026. Mr. Taylor’s intention to retire is not due to any disagreement with Resmed on any matter relating to Resmed’s operations, policies or practices.
Director Ronald Taylor will retire from the Board at the November 18, 2026 annual meeting. The filing explicitly states his retirement is not due to any disagreement with the company on operations, policies, or practices, indicating this is a routine board transition.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
The Board has appointed Carol Burt to serve as Lead Director, effective November 15, 2026. Burt has served on Resmed’s Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee.
Carol Burt, a Board member since 2013 and current chair of the Nominating and Governance Committee, will become Lead Director on November 15, 2026. She also serves on the Audit Committee and Compliance, Privacy and Quality Committee, bringing extensive governance and healthcare industry experience to the role.
Added in current filing · view on EDGAR →
Ron Taylor, Resmed’s current Lead Director, who is not standing for reelection at the company’s 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company. ... Ron Taylor joined Resmed’s Board of Directors in 2005 and has served in numerous leadership roles, including as Lead Director since 2013.
Ron Taylor, who has served on ResMed's Board since 2005 and as Lead Director since 2013, will not stand for reelection at the November 18, 2026 Annual Meeting and will retire after more than 21 years of service. This is a planned retirement following a long tenure during which he helped guide the company's governance, strategy and growth.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 18, 2026 · How we verify